Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THALOMID vs LENALIDOMIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Thalidomide is an immunomodulatory agent with antiangiogenic and anti-inflammatory properties. Its exact mechanism is not fully understood, but it inhibits tumor necrosis factor-alpha (TNF-α) production, modulates cytokine activity, and suppresses angiogenesis by inhibiting basic fibroblast growth factor (b FGF) and vascular endothelial growth factor (VEGF).
Immunomodulatory agent with anti-angiogenic and anti-proliferative properties; alters cytokine production, enhances T-cell and NK-cell activity, inhibits tumor angiogenesis, and directly induces apoptosis in tumor cells.
FDA approved: Newly diagnosed multiple myeloma (in combination with dexamethasone),FDA approved: Moderate to severe erythema nodosum leprosum (ENL) in leprosy,Off-label: Crohn's disease,Off-label: Bechet's disease,Off-label: HIV-associated wasting syndrome,Off-label: Recurrent aphthous ulcers
Multiple myeloma (in combination with dexamethasone),Myelodysplastic syndromes associated with deletion 5q,Mantle cell lymphoma (relapsed or refractory)
200 mg orally once daily, taken with water preferably at bedtime to reduce sedation; dose may be titrated up to 400 mg daily based on tolerability.
10 mg orally once daily on days 1-21 of 28-day cycle for transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes; 25 mg orally once daily on days 1-21 of 28-day cycle for relapsed/refractory multiple myeloma.
Mean terminal elimination half-life is approximately 5-7 hours in healthy adults; may be prolonged to 12-18 hours in patients with hepatic impairment due to decreased metabolism.
Terminal half-life ~3 hours (range 2-5 h) in multiple myeloma patients; prolongation in renal impairment requires dose adjustment.
Thalidomide is primarily metabolized by spontaneous hydrolysis in plasma and tissues, not by cytochrome P450 enzymes. Minor metabolism involves hydroxylation and conjugation.
Metabolized via hydrolysis and glucuronidation; CYP450 enzymes play a minor role.
Primarily renal: >80% of absorbed dose excreted unchanged in urine. Minor fecal elimination (<15%). No significant biliary excretion.
Renal: ~82% unchanged; fecal <5%; biliary negligible.
Approximately 55-66% bound to serum albumin.
~30% bound, primarily to albumin.
Apparent Vd is 0.7-1.2 L/kg, suggesting distribution into total body water with some tissue binding.
Approximately 0.6 L/kg (range 0.4-0.8 L/kg), indicating distribution into total body water.
Oral bioavailability is >90% with minimal first-pass metabolism.
Oral: ~80% (range 60-100%); food does not significantly affect absorption.
For GFR 30-60 m L/min: reduce dose by 50%; for GFR <30 m L/min or dialysis: administer 100 mg once daily; for severe renal impairment, consider alternative therapy.
For Cr Cl 30-60 m L/min: 5 mg once daily; for Cr Cl <30 m L/min not requiring dialysis: 2.5 mg once daily; for Cr Cl <30 m L/min requiring dialysis: 2.5 mg once daily post-dialysis on dialysis days.
Child-Pugh Class A: no adjustment; Child-Pugh Class B or C: use with caution, consider dose reduction; limited data for severe hepatic impairment.
No specific dose adjustment for hepatic impairment in FDA labeling; use with caution in severe hepatic impairment (Child-Pugh C) due to lack of data.
Not recommended for use in children <18 years due to lack of safety and efficacy data; in clinical trials for specific conditions (e.g., recurrent brain tumors), doses of 3-6 mg/kg/day have been used, but not approved.
Not approved in pediatric patients; safety and efficacy not established in patients <18 years.
Start at lower end of dosing range (e.g., 100 mg daily) due to increased sensitivity to sedation and thromboembolic risk; monitor renal function as elderly often have decreased GFR.
No specific dose adjustment beyond renal function; monitor for hematologic toxicity and thromboembolic events due to age-related comorbidities and renal impairment.
THALOMID is contraindicated in pregnancy due to severe life-threatening birth defects. It must never be used by females who are pregnant or could become pregnant. If thalidomide is used during pregnancy, it can cause severe birth defects or death of the fetus. Additionally, females of reproductive potential must use two effective forms of contraception or abstain from heterosexual intercourse for at least 4 weeks before starting therapy, during therapy, and for 4 weeks after discontinuing therapy.
Embryo-fetal toxicity: Can cause fetal harm. Do not use during pregnancy. Females of reproductive potential must use contraception or abstain. Hematologic toxicity: Significant neutropenia and thrombocytopenia; monitor blood counts. Deep vein thrombosis and pulmonary embolism: Increased risk; monitor and consider prophylaxis.
Venous thromboembolic events (VTE) – increased risk, especially when combined with dexamethasone,Fetal exposure – requires patient enrollment in the THALOMID REMS program,Hypersensitivity reactions – including rash, Stevens-Johnson syndrome,Peripheral neuropathy – may be irreversible, monitor for symptoms,Somnolence and dizziness – may impair ability to drive or operate machinery,Syncope and bradycardia – may occur, especially in elderly,Hepatotoxicity – monitor liver function tests,Hematologic toxicity – neutropenia and thrombocytopenia,Seizures – use with caution in patients with history of seizures
Hematologic toxicity (neutropenia and thrombocytopenia); thromboembolic events; hepatotoxicity; allergic reactions; tumor lysis syndrome; thyroid disorders; neuropathy; increased risk of second primary malignancies.
Pregnancy or women of childbearing potential not using two forms of contraception,Hypersensitivity to thalidomide or any component of the formulation,Use in females who are breastfeeding (contraindicated due to potential harm to infant)
Pregnancy; hypersensitivity to lenalidomide; concomitant use with live vaccines; breastfeeding not recommended.
Take with water on an empty stomach (at least 1 hour before or 2 hours after meals). Avoid grapefruit juice, alcohol, and high-fat meals as they may alter absorption and increase risk of side effects.
Avoid grapefruit, grapefruit juice, and Seville oranges (including marmalade) as they inhibit CYP3A4 and may increase lenalidomide exposure. No other significant food interactions. Take capsules with water; do not crush or chew.
Thalidomide is a known human teratogen. In the first trimester, exposure is associated with a high risk of severe birth defects including limb reduction defects, congenital heart disease, and anotia. No safe gestational trimester exists; contraindicated in pregnancy.
Lenalidomide is a thalidomide analogue; it is teratogenic in humans. Pregnancy category X. In the first trimester, there is a high risk of severe birth defects (e.g., limb defects, cardiac anomalies) and fetal death. No adequate studies in second or third trimester, but risk persists throughout pregnancy. Contraindicated in pregnancy.
Excretion into breast milk unknown. Due to potential for adverse effects in the nursing infant, breastfeeding is contraindicated. M/P ratio not available.
No data on lenalidomide in human milk; however, due to potential for serious adverse effects in nursing infants (including neutropenia and thrombocytopenia), breastfeeding is contraindicated during therapy and for at least 1 week after last dose. M/P ratio unknown.
Contraindicated in pregnancy; no dose adjustments applicable because thalidomide is absolutely contraindicated during pregnancy.
Lenalidomide is contraindicated in pregnancy; no dose adjustments are recommended because use is prohibited. No pharmacokinetic studies in pregnancy; however, physiological changes (e.g., increased volume of distribution, renal clearance) may alter drug levels, but given teratogenicity, dosing is not applicable.
Thalomid (thalidomide) is a potent teratogen requiring strict pregnancy prevention. It has immunomodulatory, anti-inflammatory, and anti-angiogenic properties. Used primarily for erythema nodosum leprosum (ENL) and multiple myeloma. Monitor for thromboembolic events, peripheral neuropathy, and bradycardia. Dose adjustment needed for hepatic impairment. Ensure patient enrollment in THALOMID REMS program.
Lenalidomide is an immunomodulatory drug (IMi D) with anti-angiogenic and anti-proliferative properties. It requires risk evaluation and mitigation strategy (REMS) due to teratogenicity. Monitor for thromboembolic events (DVT/PE) especially when combined with dexamethasone. Consider dose adjustment for renal impairment (Cr Cl < 60 m L/min). Baseline and periodic monitoring of CBC, thyroid function, and liver enzymes is essential. May cause tumor lysis syndrome in high tumor burden patients; ensure hydration and prophylaxis.
Thalidomide can cause severe birth defects; use two forms of contraception during treatment and for 4 weeks after stopping.,Do not take during pregnancy or if planning to become pregnant; male patients must use condoms during sexual activity.,Report any numbness, tingling, or pain in hands/feet immediately.,Seek emergency care for signs of blood clots: chest pain, shortness of breath, leg swelling, or vision changes.,Avoid alcohol and grapefruit juice as they may increase side effects.,Do not donate blood or sperm while on therapy and for 4 weeks after discontinuation.
Do not take lenalidomide if you are pregnant, breastfeeding, or planning to become pregnant; use two reliable forms of contraception during treatment and for 4 weeks after stopping.,Do not donate blood or sperm while taking lenalidomide and for 4 weeks after discontinuation.,Report any symptoms of blood clots (swelling, pain, redness in leg, sudden chest pain, shortness of breath) or signs of infection (fever, chills) immediately.,Take lenalidomide exactly as prescribed, usually once daily with a glass of water; do not break, chew, or open capsules.,Avoid grapefruit, grapefruit juice, and Seville oranges as they may affect drug metabolism.,Keep all appointments for blood tests to monitor for low blood cell counts and other side effects.
No interactions on record
"The combination of lenalidomide and leflunomide may result in additive hematologic toxicity, particularly bone marrow suppression, due to overlapping mechanisms that impair hematopoietic cell proliferation and survival. Leflunomide, via its active metabolite teriflunomide, inhibits dihydroorotate dehydrogenase (DHODH) and suppresses pyrimidine synthesis in rapidly dividing cells, while lenalidomide modulates the ubiquitin E3 ligase cereblon, leading to altered cytokine production and direct antineoplastic effects. Clinically, patients may experience increased risks of severe neutropenia, thrombocytopenia, and anemia, potentially requiring dose reductions, growth factor support, or discontinuation of one agent."
"Digoxin, a cardiac glycoside, is a P-glycoprotein (P-gp) substrate. Lenalidomide, an immunomodulatory drug, can inhibit P-gp activity, leading to increased intestinal absorption and reduced renal clearance of digoxin. This interaction may cause elevated serum digoxin levels, increasing the risk of digoxin toxicity (e.g., arrhythmias, nausea, visual disturbances)."
"Lenalidomide, an immunomodulatory drug, increases the thrombogenic potential of Mestranol, an estrogen component of oral contraceptives, by enhancing platelet aggregation and endothelial activation. This combined prothrombotic effect elevates the risk of venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism. Patients, especially those with additional risk factors, require careful monitoring for signs of thrombosis."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THALOMID vs LENALIDOMIDE, answered by our medical review team.
THALOMID is a Immunomodulatory Agent that works by Thalidomide is an immunomodulatory agent with antiangiogenic and anti-inflammatory properties. Its exact mechanism is not fully understood, but it inhibits tumor necrosis factor-alpha (TNF-α) production, modulates cytokine activity, and suppresses angiogenesis by inhibiting basic fibroblast growth factor (b FGF) and vascular endothelial growth factor (VEGF).. LENALIDOMIDE is a Immunomodulatory Agent that works by Immunomodulatory agent with anti-angiogenic and anti-proliferative properties; alters cytokine production, enhances T-cell and NK-cell activity, inhibits tumor angiogenesis, and directly induces apoptosis in tumor cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THALOMID and LENALIDOMIDE depend on the specific clinical indication. These are both Immunomodulatory Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THALOMID is: 200 mg orally once daily, taken with water preferably at bedtime to reduce sedation; dose may be titrated up to 400 mg daily based on tolerability.. The standard adult dose of LENALIDOMIDE is: 10 mg orally once daily on days 1-21 of 28-day cycle for transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes; 25 mg orally once daily on days 1-21 of 28-day cycle for relapsed/refractory multiple myeloma.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THALOMID and LENALIDOMIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THALOMID is classified as Category C. Thalidomide is a known human teratogen. In the first trimester, exposure is associated with a high risk of severe birth defects including limb reduction defects, congenital heart d. LENALIDOMIDE is classified as Category C. Lenalidomide is a thalidomide analogue; it is teratogenic in humans. Pregnancy category X. In the first trimester, there is a high risk of severe birth defects (e.g., limb defects,. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.